Answers are grounded in this paper and cite their sources.
Critical commentary highlights ethical and safety oversight failures in baclofen trials for high-risk drinkers, suggesting stricter regulatory compliance for off-label pharmacotherapy.
Rigal et al.'s retrospective analysis on the effect of baclofen in a series of 132 high-risk drinkers deserves comments because it challenged several basic principles (Rigal et al., 2012). First, it is not clear whether non-pharmacological intervention was systematically offered, even though some research has found that brief physician advice can help some alcohol-dependent patients (e.g. Grossberg et al., 2004; Fleming et al., 2010) Second, Rigal et al. bypassed the usual phase II step in pharmacotherapy trials, that is, to determine the most effective and safe dose. They have not spelt out their grounds to justify a dose of 145 ± 75 mg/day (max = 400). Thirdly, although patients would presumably have been told that that off-label prescription is not reimbursed by the French mandatory national health insurance scheme, it is not clear what they were told about medical liability insurance. Usually, the doctor's own medical indemnity insurance covers prescribing off-licence when it is based upon expert opinion, but it is not clear whether that would have been the case for these patients. Lastly, the authors chose to avoid a review by a research ethics committee, regarding their research as an audit. Such a review would have meant an external review of the information and consent documents; and might have recommended specific insurance. In the period since this study was conducted, the French medication control agency, Afssaps (L'Agence française de sécurité sanitaire des produits de santé) warned against off-label prescription of baclofen for alcoholics on the basis that evidence was lacking, pending a planned randomized controlled trial in France (Afssaps, 2011). However, this was revoked in April 2012, with a statement that the use of baclofen could be considered on an individual basis with dose adjustment because new observational data had shown clinical benefit (Afssaps, 2012).
No takes yet. Share an insight, caveat, or question.
Alain Braillon (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: